- Report
- April 2025
- 192 Pages
Global
From €4733EUR$4,950USD£3,962GBP
- Report
- May 2024
- 130 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1195EUR$1,250USD£1,000GBP
- Report
- February 2022
- 32 Pages
Global
From €1912EUR$2,000USD£1,601GBP
Nocturia is a condition characterized by frequent nighttime urination. It is often treated with drugs that act on the central nervous system (CNS). These drugs work by reducing the amount of urine produced at night, allowing the patient to sleep through the night without having to get up to urinate. Common CNS drugs used to treat nocturia include anticholinergics, alpha-blockers, and diuretics. Anticholinergics work by blocking the action of acetylcholine, a neurotransmitter that stimulates the bladder. Alpha-blockers work by blocking the action of adrenaline, which can cause the bladder to contract. Diuretics work by increasing the amount of urine produced, allowing the patient to urinate more frequently during the day and less at night.
Companies in the nocturia drug market include Pfizer, Merck, Novartis, and AstraZeneca. Show Less Read more